346 Phase 1a study of the safety, pharmacokinetics, and pharmacodynamics of GDC-0919 in patients with recurrent/advanced solid tumors

Promote Suppressive cytokines • IDO1-expressing cells regulate inflammation and immune response to foreign as well as non pathological antigens • Several cancers induce the IDO1 pathway in tumor and host immune cells, permitting immune escape and the attainment of immunologic tolerance • GDC-0919 (RO 7077339; previously NLG919) is a small molecule investigational immunotherapy designed to inhibit IDO1 for the treatment of immune tolerance associated with cancer (Mautino et al.; 2013), intended as combination therapy